---
layout: default
title: Treprostinil
description: "Treprostinil çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 184
evidence_level: L2
indication_count: 10
---

# Treprostinil

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Treprostinilï¼šå¾è‚ºå‹•è„ˆé«˜å£“åˆ°ç›¸é—œä½µç™¼ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Treprostinil å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Treprostinil (å‹µè„ˆå±•ç´ ) åŸæœ¬ç”¨æ–¼æ²»ç™‚ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¤šç¨®è‚ºå‹•è„ˆé«˜å£“ç›¸é—œç–¾ç—…**æœ‰æ•ˆï¼Œ
å…¶ä¸­**çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œè‚ºå‹•è„ˆé«˜å£“**æœ‰æœ€å¼·çš„è‡¨åºŠè­‰æ“šæ”¯æŒã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (WHO functional class III/IV) |
| é æ¸¬æ–°é©æ‡‰ç—‡ | pulmonary arteriovenous malformation (disease)ã€pulmonary arterial hypertensionã€pulmonary arterial hypertension associated with congenital heart diseaseã€pulmonary arterial hypertension associated with HIV infectionã€pulmonary arterial hypertension associated with chronic hemolytic anemiaã€pulmonary arterial hypertension associated with connective tissue diseaseã€pulmonary arterial hypertension associated with schistosomiasisã€hypotrichosis simplex of the scalpã€congenital hypotrichosis miliaã€malformation syndrome with odontal and/or periodontal component |
| TxGNN æœ€é«˜é æ¸¬åˆ†æ•¸ | 99.70% (è‚ºå‹•éœè„ˆç•¸å½¢) |
| è­‰æ“šç­‰ç´š | L2 (çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œ PAH) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 25 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |

## é æ¸¬æ–°é©æ‡‰ç—‡ä¸€è¦½

| ç–¾ç—…åç¨± | TxGNN åˆ†æ•¸ | è‡¨åºŠè©¦é©— | æ–‡ç»æ•¸ |
|---------|-----------|---------|-------|
| è‚ºå‹•éœè„ˆç•¸å½¢ | 99.70% | 0 | 0 |
| å…ˆå¤©æ€§å¿ƒè‡Ÿç—…ç›¸é—œ PAH | 99.60% | 2 | 20+ |
| HIV æ„ŸæŸ“ç›¸é—œ PAH | 99.55% | 1 | 5 |
| çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œ PAH | 99.55% | 2 | 20+ |
| æ…¢æ€§æº¶è¡€æ€§è²§è¡€ç›¸é—œ PAH | 99.55% | 0 | 0 |
| è¡€å¸èŸ²ç—…ç›¸é—œ PAH | 99.55% | 0 | 0 |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. pulmonary arteriovenous malformation (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.70%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Treprostinil æ˜¯ä¸€ç¨®å‰åˆ—ç’°ç´ é¡ä¼¼ç‰©ï¼Œå…¶ä½œç”¨æ©Ÿè½‰æ”¯æŒåœ¨å„é¡è‚ºå‹•è„ˆé«˜å£“ä¸­çš„æ‡‰ç”¨ï¼š</p>

<ol>
<li><strong>è¡€ç®¡æ“´å¼µ</strong>ï¼šç›´æ¥æ“´å¼µè‚ºè¡€ç®¡åŠå…¨èº«è¡€ç®¡</li>
<li><strong>æŠ—è¡€å°æ¿ä½œç”¨</strong>ï¼šæŠ‘åˆ¶è¡€å°æ¿èšé›†</li>
<li><strong>æŠ—å¢æ®–ä½œç”¨</strong>ï¼šæŠ‘åˆ¶è¡€ç®¡å¹³æ»‘è‚Œç´°èƒå¢æ®–</li>
<li><strong>ç´°èƒä¿è­·ä½œç”¨</strong>ï¼šä¿è­·å…§çš®ç´°èƒåŠŸèƒ½</li>

</ol>
<p>é€™äº›æ©Ÿè½‰é©ç”¨æ–¼å„ç¨®ç—…å› å°è‡´çš„è‚ºå‹•è„ˆé«˜å£“ï¼ŒåŒ…æ‹¬çµç· çµ„ç¹”ç–¾ç—…ã€å…ˆå¤©æ€§å¿ƒè‡Ÿç—…ã€HIV æ„ŸæŸ“ç­‰ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>### çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œ PAH</p>
<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>äººæ•¸</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>ç›¸é—œè©¦é©—</td>
<td>Phase 2/3</td>
<td>COMPLETED</td>
<td>N/A</td>
<td>Treprostinil å¯æ”¹å–„ CTD-PAH æ‚£è€…çš„é‹å‹•è€åŠ›åŠè¡€æµå‹•åŠ›å­¸åƒæ•¸</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>æœŸåˆŠ</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/15302727/">15302727</a></td>
<td>2004</td>
<td>RCT</td>
<td>Chest</td>
<td>Treprostinil çš®ä¸‹æ³¨å°„æ²»ç™‚ CTD-PAH çš„ç™‚æ•ˆèˆ‡å®‰å…¨æ€§</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/11897647/">11897647</a></td>
<td>2002</td>
<td>RCT</td>
<td>Ann Intern Med</td>
<td>Treprostinil åœ¨è‚ºå‹•è„ˆé«˜å£“ä¸­çš„ç™‚æ•ˆ</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/22621693/">22621693</a></td>
<td>2012</td>
<td>Review</td>
<td>Drugs</td>
<td>CTD-APAH æ²»ç™‚æŒ‡å—å»ºè­°ä½¿ç”¨ Treprostinil (I-B æ¨è–¦)</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/41594679/">41594679</a></td>
<td>2026</td>
<td>Review</td>
<td>Biomolecules</td>
<td>è¨è«– CTD-PAH ç›®å‰æ²»ç™‚ç­–ç•¥åŠå¸å…¥å¼ Treprostinil çš„è§’è‰²</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/22291467/">22291467</a></td>
<td>2012</td>
<td>Review</td>
<td>Drug Des Devel Ther</td>
<td>å¸å…¥å¼ Treprostinil çš„è‡¨åºŠæ‡‰ç”¨å›é¡§</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. pulmonary arterial hypertension associated with congenital heart disease</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.60%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01383083" target="_blank">NCT01383083</a></td><td>N/A</td><td>UNKNOWN</td><td>42</td><td>Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hyperten...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02261883" target="_blank">NCT02261883</a></td><td>PHASE2</td><td>TERMINATED</td><td>42</td><td>Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Pers...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ19 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35412560/" target="_blank">35412560</a></td><td>2022</td><td>Article</td><td>JAMA</td><td>Diagnosis and Treatment of Pulmonary Arterial Hypertension: ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29436381/" target="_blank">29436381</a></td><td>2018</td><td>Article</td><td>Heart (British Cardi</td><td>Subcutaneous treprostinil in congenital heart disease-relate...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21852894/" target="_blank">21852894</a></td><td>2009</td><td>Article</td><td>Progress in pediatri</td><td>Non-congenital heart disease associated pediatric pulmonary ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16919006/" target="_blank">16919006</a></td><td>2006</td><td>Article</td><td>European journal of </td><td>Current treatment options in children with pulmonary arteria...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16725066/" target="_blank">16725066</a></td><td>2006</td><td>Article</td><td>Cardiology in the yo</td><td>Bosentan for the treatment of pulmonary arterial hypertensio...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 14 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pulmonary arterial hypertension associated with HIV infection</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00494533" target="_blank">NCT00494533</a></td><td>PHASE4</td><td>TERMINATED</td><td>45</td><td>Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomiz...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14720012/" target="_blank">14720012</a></td><td>2003</td><td>Article</td><td>American journal of </td><td>Prostanoids for pulmonary arterial hypertension.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18473715/" target="_blank">18473715</a></td><td>2008</td><td>Article</td><td>Expert opinion on ph</td><td>Treprostinil for the treatment of pulmonary hypertension.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18260882/" target="_blank">18260882</a></td><td>2007</td><td>Article</td><td>Kardiologiia</td><td>[Pulmonary hypertension and right ventricular failure. Part ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary arterial hypertension associated with chronic hemolytic anemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. pulmonary arterial hypertension associated with connective tissue disease</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02663895" target="_blank">NCT02663895</a></td><td>PHASE2</td><td>COMPLETED</td><td>12</td><td>A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Tr...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ19 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35412560/" target="_blank">35412560</a></td><td>2022</td><td>Article</td><td>JAMA</td><td>Diagnosis and Treatment of Pulmonary Arterial Hypertension: ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38378970/" target="_blank">38378970</a></td><td>2024</td><td>Article</td><td>Internal and emergen</td><td>Treatment of pulmonary arterial hypertension in patients wit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11897647/" target="_blank">11897647</a></td><td>2002</td><td>Article</td><td>American journal of </td><td>Continuous subcutaneous infusion of treprostinil, a prostacy...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37765060/" target="_blank">37765060</a></td><td>2023</td><td>Article</td><td>Pharmaceuticals (Bas</td><td>Recent Advances in the Treatment of Pulmonary Arterial Hyper...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40566626/" target="_blank">40566626</a></td><td>2025</td><td>Article</td><td>Life (Basel, Switzer</td><td>Efficacy and Safety of Selexipag Treatment in Connective Tis...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 14 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. pulmonary arterial hypertension associated with schistosomiasis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hypotrichosis simplex of the scalp</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.48%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. congenital hypotrichosis milia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.30%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. malformation syndrome with odontal and/or periodontal component</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.21%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35688447/" target="_blank">35688447</a></td><td>2022</td><td>Article</td><td>Journal of clinical </td><td>Treatment of stage IV periodontitis: The EFP S3 level clinic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37435999/" target="_blank">37435999</a></td><td>2023</td><td>Article</td><td>Periodontology 2000</td><td>Complications and treatment errors related to regenerative p...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35420698/" target="_blank">35420698</a></td><td>2022</td><td>Article</td><td>The Cochrane databas</td><td>Treatment of periodontitis for glycaemic control in people w...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9495612/" target="_blank">9495612</a></td><td>1998</td><td>Article</td><td>Journal of clinical </td><td>Microbial complexes in subgingival plaque.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22057194/" target="_blank">22057194</a></td><td>2012</td><td>Article</td><td>Diabetologia</td><td>Periodontitis and diabetes: a two-way relationship.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. Ambras type hypertrichosis universalis congenita</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.17%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨ç½•è—¥è¼¸å­—ç¬¬000071è™Ÿ | å‹µè„ˆå±•ç´ æ³¨å°„åŠ‘1æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (WHO class III/IV) |
| è¡›éƒ¨ç½•è—¥è¼¸å­—ç¬¬000072è™Ÿ | å‹µè„ˆå±•ç´ æ³¨å°„åŠ‘2.5æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (WHO class III/IV) |
| è¡›éƒ¨ç½•è—¥è¼¸å­—ç¬¬000074è™Ÿ | å‹µè„ˆå±•ç´ æ³¨å°„åŠ‘10æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (WHO class III/IV) |
| è¡›éƒ¨ç½•è—¥è¼¸å­—ç¬¬000096è™Ÿ | æ³°è‚ºèˆ’å£è…”å¸å…¥æ¶² | å£è…”å¸å…¥åŠ‘ | ç‰¹ç™¼æ€§æˆ–éºå‚³æ€§è‚ºå‹•è„ˆé«˜å£“ (NYHA class III) |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬029038è™Ÿ | æ‹“è‚ºé¬†å£è…”å¸å…¥æ¶² | å£è…”å¸å…¥åŠ‘ | é–“è³ªæ€§è‚ºç—…é€ æˆçš„è‚ºé«˜å£“ |

## å®‰å…¨æ€§è€ƒé‡

- **çµ¦è—¥é€”å¾‘**ï¼šçš®ä¸‹æ³¨å°„å¯èƒ½å¼•èµ·æ³¨å°„éƒ¨ä½ç–¼ç—›åŠåæ‡‰
- **è¡€å£“å½±éŸ¿**ï¼šå¯èƒ½å¼•èµ·ä½è¡€å£“
- **å‡ºè¡€é¢¨éšª**ï¼šæŠ—è¡€å°æ¿ä½œç”¨å¯èƒ½å¢åŠ å‡ºè¡€é¢¨éšª
- **ä¸»è¦äº¤äº’ä½œç”¨ (Moderate)**ï¼š
  - Acetylsalicylic acidï¼ˆå¢åŠ å‡ºè¡€é¢¨éšªï¼‰
  - SGLT2 æŠ‘åˆ¶åŠ‘ï¼ˆCanagliflozinã€Dapagliflozinã€Empagliflozinï¼‰
  - Epinephrineï¼ˆå¯èƒ½å½±éŸ¿è¡€å£“èª¿ç¯€ï¼‰


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Hemorrhage** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€‚

**Diverticulum** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šThe tablet shell of the manufactured form of treprostinil, Orenitram does not dissolve and can lodge in the diverticulum of patients with diverticulos...

**ä½è¡€å£“** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Pneumonia** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚

**Hepatic Insufficiency** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Treprostinil åœ¨çµç· çµ„ç¹”ç–¾ç—…ç›¸é—œè‚ºå‹•è„ˆé«˜å£“ä¸­å·²æœ‰å……åˆ†çš„è‡¨åºŠè­‰æ“šæ”¯æŒï¼Œæ­æ´²æ²»ç™‚æŒ‡å—å·²å°‡å…¶åˆ—ç‚º I-B ç­‰ç´šæ¨è–¦ã€‚å°æ–¼å…¶ä»–é æ¸¬çš„é©æ‡‰ç—‡ï¼ˆå¦‚å…ˆå¤©æ€§å¿ƒè‡Ÿç—…ç›¸é—œ PAHï¼‰ï¼Œä¹Ÿæœ‰è‡¨åºŠè©¦é©—å’Œæ–‡ç»æ”¯æŒã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡å°ç‰¹å®šäºå‹ï¼ˆå¦‚ HIV ç›¸é—œ PAHï¼‰çš„é€²ä¸€æ­¥ç ”ç©¶
- å¸å…¥å¼åŠ‘å‹åœ¨ä¸åŒ PAH äºå‹ä¸­çš„ç™‚æ•ˆè©•ä¼°
- èˆ‡å…¶ä»– PAH æ²»ç™‚è—¥ç‰©çš„æ¯”è¼ƒç ”ç©¶

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Povidone]({{ "/drugs/povidone/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Irbesartan]({{ "/drugs/irbesartan/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cytarabine]({{ "/drugs/cytarabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Atezolizumab]({{ "/drugs/atezolizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Remdesivir]({{ "/drugs/remdesivir/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Treprostinilè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/treprostinil/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_treprostinil,
  title = {Treprostinilè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/treprostinil/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
